Here are three stocks with buy rank and strong value characteristics for investors to consider today, March 16:OptimizeRx Corporation (OPRX) : This digital healthcare technology company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing by 12.6% over the last 60 days.OptimizeRx has a price-to-earnings ratio (P/E) of 6.53 compared with 17.60 for the industry. The company possesses a Value Scoreof A.Envista Holdings Corporation (NVST) : This dental ...

Revenue Concentration and Growth - OptimizeRx's top five customers accounted for approximately 47% of its revenues in 2025, indicating a high revenue concentration risk [56]. - The company reported that its top five customers represented approximately 47% of revenue for the year ended December 31, 2025 [88]. - The company generated 62% and 57% of its revenue through its two largest channel partners in 2025 and 2024, respectively [91]. - The company employs a "land and expand" strategy to grow its existing customer base and generate consistent revenues [207]. - The company aims to transition its DAAP customers to a subscription-based model to improve margins and revenue predictability [208]. Market Potential and Industry Trends - The total pharmaceutical industry digital spend in the United States has surpassed $20 billion, highlighting significant market potential for digital marketing solutions [42]. - The life sciences industry is increasingly shifting towards precision digital marketing, creating opportunities for OptimizeRx's tailored solutions [39]. - The company expects seasonal trends in the pharmaceutical brand marketing industry to continue, impacting revenue fluctuations [83]. - Seasonality trends in the pharmaceutical brand marketing industry lead to lower revenue in the first quarter, with gradual increases in subsequent quarters [211]. Financial Performance - Net revenue increased by 19% to $109,429 for the year ended December 31, 2025, compared to $92,127 for 2024, driven by growth across all solutions, particularly DAAP and DTC related sales [221]. - Net revenue retention was 116% for 2025, down from 121% in 2024, primarily due to the timing of the Medicx Health acquisition [218]. - Revenue per average full-time employee increased to $839, up from $701 in 2024, indicating improved productivity [219]. - Gross profit for 2025 was $73,595, representing a gross margin of 67.3%, compared to $59,378 and a gross margin of 64.5% in 2024 [220]. - Operating expenses decreased by approximately 15% to $61,902 in 2025 from $73,084 in 2024 [224]. - Net income for 2025 was $5,132, a significant recovery from a net loss of $20,110 in 2024 [234]. - Cost of revenues as a percentage of revenue improved to approximately 33% in 2025 from approximately 36% in 2024 [222]. - Interest expense decreased to $5,294 in 2025 from $6,160 in 2024, reflecting lower interest rates and a reduced average principal balance [231]. - Income tax expense for 2025 was $1,818, with an effective rate of 26.2%, compared to $725 and an effective rate of (3.7)% in 2024 [233]. Innovation and Technology - The Dynamic Audience Activation Platform (DAAP) utilizes machine learning to identify and engage healthcare providers (HCPs) and patients, enhancing marketing effectiveness [35]. - The Micro-Neighborhood® Targeting (MNT) solution targets geographies with eligible patients, covering over 90% of the U.S. population, while maintaining privacy [36]. - OptimizeRx's technology platform integrates advanced features of a Supply-Side Platform (SSP) to manage and optimize point-of-care media campaigns [53]. - The company holds five patents and has two pending patent applications as of December 31, 2025, reflecting its commitment to innovation and intellectual property protection [62]. - The company plans to grow by integrating technology into electronic platforms, which will demand significant management and financial resources [120]. Regulatory and Compliance Risks - The company is subject to regulatory pressures that may affect its advertising practices, particularly regarding personal information processing [65]. - Regulatory compliance costs are significant and expected to rise, with potential liabilities for non-compliance that could adversely affect the company's operations and financial performance [99]. - The evolving data protection landscape may impose additional compliance burdens and costs on the company, impacting its ability to operate effectively [103]. - Changes in regulations, such as those related to drug pricing and marketing practices, could adversely affect the company's business and financial condition [109]. - The company faces risks related to potential legal challenges and litigation costs associated with its intellectual property, which could impact its financial condition [114]. Operational Challenges - The company has a history of losses, with profitability achieved only in 2021 and 2025, primarily due to investments in future growth [77]. - The company is experiencing customer growth but acknowledges that attracting new customers and retaining existing ones may require increasingly sophisticated and costly sales and marketing efforts [93]. - The competitive landscape is intensifying, with numerous companies vying for revenue from healthcare advertisers and sponsors, which may impact the company's market share [94]. - Many competitors possess greater financial and technical resources, which could hinder the company's ability to compete effectively [95]. - The company faces challenges in managing growth effectively, which could strain operations and impact customer satisfaction if not addressed [136][137]. Cybersecurity and Data Protection - Cybersecurity incidents could lead to reputational damage, loss of customers, and increased costs, potentially affecting competitiveness and operational results [116]. - The company employs extensive cybersecurity measures, but cannot guarantee their adequacy against evolving threats, which may require significant management resources [117]. - The company has a cybersecurity insurance policy with a coverage limit of up to $20 million, which includes various protections against cyber incidents [177]. - The company has implemented a comprehensive risk management process to identify and manage material risks from cybersecurity threats [171]. - The Board has tasked the Audit Committee with overseeing the company's cybersecurity risk management processes [182]. Employee and Organizational Structure - As of December 31, 2025, the company had 104 full-time employees and 1 part-time employee in the U.S., along with 28 full-time employees in Croatia [66]. - The company has increased its focus on training and development for employees, implementing a Learning Management System for tracking training [67]. - The company has a good relationship with its employees and has not experienced any work stoppages [66]. - The company may face challenges in attracting and retaining key personnel, which is critical for executing its business strategy [152]. Financial Position and Future Outlook - The company obtained a $40 million term loan in 2023 to partially finance the acquisition of Medicx Health [81]. - The company does not expect to pay dividends in the foreseeable future, focusing on retaining funds for growth [157]. - The stock price has experienced significant volatility, influenced by various factors beyond the company's control, which may affect liquidity [156]. - Interest rate increases could adversely affect financial condition, with a one-percentage-point increase in interest rates potentially raising interest expenses by approximately $292 for the year ended December 31, 2025 [140]. - The company faces significant risks from international operations, including regulatory, economic, and political challenges that may differ from those in the United States [141]. - Inflationary pressures in domestic markets were significant in 2024, with a decrease in 2025, but future increases remain uncertain, potentially affecting demand for products [143]. - The company recorded an impairment charge of $368 million for technology-related assets in 2025 due to non-renewal of a contract, impacting financial results [148]. - Goodwill on the balance sheet as of December 31, 2025, was approximately $70.869 billion, with intangible assets netting around $40.796 billion [149]. - The company recorded impairment charges related to goodwill of approximately $0 and $7.489 million for the years ended December 31, 2025, and 2024, respectively [149]. - Geopolitical events, such as the conflict between Russia and Ukraine, may adversely affect customer spending on technology products and services [151].

Core Viewpoint - OptimizeRx (OPRX) has experienced a significant decline in stock price, dropping from the $20s to single digits, largely attributed to the AI-fear trade [1] Company Performance - The stock's recent performance reflects broader market trends affecting growth and momentum stocks, which are perceived as reasonably priced yet likely to outperform in the long term [1] Investment Strategy - The focus is on investing in high-quality growth stocks, with a historical reference to the S&P 500 increasing by 367% and the Nasdaq by 685% from 2009 to 2019, indicating potential for long-term gains [1]

Core Viewpoint - OptimizeRx Corp is experiencing significant stock price decline due to market volatility and uncertainty regarding Most Favored Nation (MFN) pricing [1] Financial Performance - The company reported fourth-quarter earnings of 51 cents, surpassing the consensus estimate of 23 cents [2] - Revenues increased to $32.2 million, exceeding the consensus of $31.1 million, with adjusted EBITDA at $12.0 million [2] Future Guidance - OptimizeRx revised its fiscal year 2026 revenue guidance to between $109 million and $114 million, down from the previous range of $118 million to $124 million [3] - Adjusted EBITDA for 2026 is projected to be between $21 million and $25 million, reflecting cautious customer spending [3] Market Sentiment - The CEO anticipates that advancements in AI will allow customers to shift marketing budgets towards areas where OptimizeRx can provide significant ROI, potentially enhancing the company's market position over time [4] - The stock is currently trading 19.7% below its 20-day simple moving average and 50.1% below its 100-day simple moving average, indicating a bearish trend [4] Stock Performance - Over the past 12 months, shares have risen by 42.80%, but are closer to their 52-week lows, indicating potential challenges for upward momentum [5] - The RSI is at 34.00, considered neutral, while the MACD shows bullish momentum as it is above the signal line [5] Analyst Consensus - The stock has a Buy Rating with an average price target of $23.08, although it is performing poorly relative to peers with a Value Rank of 0.51 [7] - Key resistance is identified at $8.50 and key support at $6.00 [8] Overall Assessment - The Benzinga Edge signal indicates a 'High-Flyer' setup, with a healthy balance sheet but low Value and Momentum scores suggesting underperformance [9] - At the time of publication, OptimizeRx shares were down 17.53% at $6.21 [9]

Core Insights - OptimizeRx reported strong fiscal 2025 results, with revenue of $109.4 million and adjusted EBITDA of $24.3 million, exceeding both internal expectations and consensus estimates [2][5] - The company experienced growth from established customers and increased contributions from mid-tier and long-tail life sciences companies [2][14] - Management updated the 2026 outlook, anticipating revenue of $109–114 million and adjusted EBITDA of $21–25 million, citing early-year softness in contracted revenue due to shifting customer spending patterns [4][19] Financial Performance - For Q4 2025, OptimizeRx achieved revenue of $32.2 million and adjusted EBITDA of $12.0 million, with a gross margin of 74.8%, up from 68.1% in the previous year [5][6] - Net income for Q4 was $5.0 million, or $0.26 per fully diluted share, compared to a net loss of $0.1 million in Q4 2024 [7] - Operating cash flow for 2025 was $18.7 million, significantly higher than $4.9 million in 2024, with cash and short-term investments rising to $23.4 million from $13.4 million [8] Strategic Initiatives - The board authorized a $10 million share repurchase program while prioritizing debt paydown, with current debt at $26.3 million [3][13] - Management highlighted the potential of artificial intelligence as a commercial tailwind, suggesting it could enhance efficiency in marketing budgets and channel partner distribution [16] - The company is focusing on expanding point-of-prescribe connectivity and integrating with EHR systems to improve workflow embedding [17] Market Dynamics - Management noted a market shift away from managed services, which contributed approximately $9 million in the first half of 2025, leading to a more conservative spending tone among clients [9][10] - Contracted revenue, excluding managed services, is running 15% to 20% behind normal expectations due to shorter contract durations [12] - Average revenue per top 20 pharmaceutical manufacturer decreased to $2.8 million from $3.0 million in 2024, attributed to lower buy-ups and data-related revenue [15]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with full-year revenue totaling $109.4 million, reflecting strong performance [3][14] - Adjusted EBITDA for Q4 2025 was $12 million, and for the full year, it was $24.3 million, indicating more than doubled year-over-year growth [3][16] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [14][15] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [16] Business Line Data and Key Metrics Changes - The company saw solid performance across both established clients and a growing number of mid-tier and long-tail life science companies, which are viewed as attractive for future growth [3][4] - Average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups [18] Market Data and Key Metrics Changes - The company is experiencing a broader pause in spending across its client base, with clients adopting a more conservative approach due to market shifts and negotiations related to Most-Favored-Nation pricing [4][22] - The net revenue retention rate remained strong at 116%, indicating effective customer retention despite market challenges [18] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue stream [89] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [7] - The company aims to leverage AI as a tool for efficiency, enhancing marketing execution rather than being disrupted by it [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that current market softness is temporary and expects normalization in client spending in the coming months [5][22] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expected revenue between $109 million and $114 million [5][18] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail segments of the market [5][46] Other Important Information - The company ended 2025 with cash and short-term investments totaling $23.4 million, up from $13.4 million in 2024, despite paying down $8 million in principal [17] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [11][12] Q&A Session Summary Question: Are you seeing conservatism across all clients or just those in MFN negotiations? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [22] Question: Are there nuances between DTC and HCP marketing pressures? - Management indicated that both DTC and HCP marketing are experiencing similar pressures from clients [23] Question: What drove the high gross margins in Q4, and why might they not be sustainable? - Management explained that a favorable mix of channel partners contributed to high margins, but they expect margins to normalize to the mid-60% range in 2026 [25][26] Question: How is AI impacting operations? - Management sees AI as an enabler for efficiency, allowing clients to reallocate spending from content creation to commercial execution [29][75] Question: What is the current percentage of revenue under contract? - Management indicated they are running approximately 15%-20% behind last year's contracted revenue due to shorter contract durations [35][36] Question: How does the guidance for 2026 account for managed services? - The guidance includes very little from managed services, which is considered an episodic solution [40] Question: What strategies are in place to capture mid-tier and smaller manufacturers? - The company is positioned to fill gaps for mid-tier clients lacking extensive marketing resources, leading to faster-than-expected growth in this segment [45][46]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with full-year revenue totaling $109.4 million, reflecting strong performance [3][14] - Adjusted EBITDA for Q4 2025 was $12 million, and for the full year, it was $24.3 million, more than doubling year-over-year [3][16] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [14][15] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [16] Business Line Data and Key Metrics Changes - The company saw solid performance across both established clients and a growing number of mid-tier and long-tail life science companies, which are viewed as attractive for future growth [3][4] - Average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups [18] Market Data and Key Metrics Changes - The company is experiencing a broader pause in spending across its client base, particularly among those involved in Most-Favored-Nation negotiations [4][22] - The net revenue retention rate remains strong at 116%, indicating effective customer retention despite market challenges [18] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue component [89] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [7] - The company aims to leverage AI to enhance operational efficiency and marketing execution, positioning itself as a strategic partner rather than a commoditized software solution [8][29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that current market softness is temporary and expects normalization in client spending in the coming months [4][5] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expected revenue between $109 million and $114 million [5][18] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail segments of the market [5][46] Other Important Information - The company achieved Rule of 40 performance and generated nearly $19 million in free cash flow from operations in 2025 [6][17] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [11][12] Q&A Session Summary Question: Are you seeing conservatism across all clients or just those in MFN negotiations? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [22] Question: Are there differences in spending pressure between DTC and HCP marketing? - Management indicated that spending pressure is consistent across both DTC and HCP marketing [23] Question: What drove the high gross margins in Q4 2025, and why are they not sustainable? - Management explained that the high margins were due to a favorable mix of channel partners and do not expect to maintain that level in 2026 [25][26] Question: How is AI impacting operations? - Management stated that AI is enhancing efficiency and allowing clients to reallocate budgets towards execution rather than content creation [28][29] Question: What is the current percentage of revenue under contract? - Management indicated that they are running approximately 15%-20% behind last year's contracted revenue numbers due to shorter contract durations [35][37] Question: How does the guidance for 2026 account for managed services? - Management clarified that the guidance includes very little from managed services, which is considered an episodic solution [40] Question: What strategies are in place to capture the mid-tier and long-tail market? - Management highlighted their ability to fill gaps for mid-tier clients lacking large marketing budgets, leading to faster-than-expected growth in that segment [45][46]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $32.2 million, with adjusted EBITDA of $12 million, exceeding both consensus estimates and internal expectations [3][12] - Full year revenue totaled $109.4 million, with adjusted EBITDA of $24.3 million, demonstrating the strength of the operating model [3][5] - Gross margin increased from 68.1% in Q4 2024 to 74.8% in Q4 2025, attributed to a favorable product mix and channel partner strategy [13][14] - Net income for Q4 2025 was $5 million, or $0.26 per diluted share, compared to a net loss of $0.1 million in Q4 2024 [15] - Cash and short-term investments increased to $23.4 million as of December 31, 2025, from $13.4 million a year earlier [16] Business Line Data and Key Metrics Changes - The average revenue per top 20 pharmaceutical manufacturer declined slightly from $3 million in 2024 to $2.8 million in 2025, primarily due to lower buy-ups and data-related revenue [17] - The net revenue retention rate remained strong at 116%, indicating solid customer retention and growth [17] Market Data and Key Metrics Changes - There is a noted softness in year-to-date contracted revenue numbers compared to the previous year, driven by a market shift away from managed services [4][5] - The company is seeing a broader pause across clients as they adjust to Most-Favored-Nation pricing negotiations, impacting spending behavior [21][22] Company Strategy and Development Direction - The company is focused on transitioning more customers to a subscription-based model to enhance revenue predictability and establish a consistent recurring revenue component [87] - A $10 million share repurchase program has been authorized, reflecting confidence in the long-term value of the business [6] - The company aims to capture additional market share within the pharma industry's multi-billion dollar digital ecosystem, emphasizing its role as a strategic partner [11][87] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence that the current market softness is temporary and expects normalization in spending behavior over the coming months [5][21] - The guidance for 2026 has been updated to reflect a more conservative revenue outlook, with expectations of $109 million to $114 million [5][17] - Management believes there is significant opportunity for value creation, particularly in the mid-tier and long-tail life science companies [3][5] Other Important Information - The company has experienced minimal disruption from AI and views it as a potential tailwind, enabling clients to reallocate marketing budgets towards execution rather than content creation [6][28] - The company is uniquely positioned with a comprehensive commercialization platform that integrates advanced patient-finding capabilities [10][11] Q&A Session Summary Question: Are you seeing conservatism only with the companies in MFN negotiations or is it broader? - Management noted a broader pause across all clients as they digest the implications of MFN negotiations, leading to shorter contract durations [21] Question: Are there nuances between DTC and HCP marketing pressures? - Management indicated that both DTC and HCP marketing are experiencing similar pressures from manufacturers [22] Question: Can you elaborate on the gross margin drivers and sustainability? - Management explained that Q4 2025 had a favorable mix of channel partners driving higher margins, but does not expect this level to be sustainable throughout 2026 [23][25] Question: How is AI impacting operations? - Management stated that AI is creating efficiencies and enabling clients to focus more on commercial execution rather than content creation [27][28] Question: What is the current percentage of revenue under contract? - Management indicated that they are running approximately 15%-20% behind last year's contracted revenue numbers due to shorter contract durations [34][36] Question: What is the guidance for managed services in 2026? - Management stated that the guidance includes very little from managed services, as it is considered an episodic solution [40] Question: What strategies are being employed to capture mid-tier and smaller manufacturers? - Management highlighted the ability to supplement the marketing efforts of mid-tier and long-tail clients, filling gaps in their infrastructure [45][46] Question: How will capital be deployed between debt repayment and share buybacks? - Management indicated that they will evaluate opportunities as they arise, with a historical focus on paying down debt with excess cash flow [49] Question: What are the expectations for net revenue retention in 2026? - Management aims for a net revenue retention rate above 100%, indicating a positive outlook for customer retention [50]

Core Insights - OptimizeRx Corp. reported strong financial results for Q4 2025, with revenue of $32.2 million and adjusted EBITDA of $12.0 million, exceeding both consensus and internal expectations [4][8] - The company achieved a record full-year revenue of $109.4 million, reflecting a 19% increase from $92.1 million in 2024, and demonstrated a profitable growth model with a margin exceeding 20% [4][8] - The company is focused on becoming a sustainable "Rule of 40" company, indicating a balance between growth and profitability [4] Financial Highlights - Q4 gross profit increased by 9% year-over-year to $24.1 million, up from $22.0 million in Q4 2024 [7][8] - Q4 net income reached $5.0 million, or $0.26 per diluted share, compared to a net loss of $(0.1) million in the same period of 2024 [8] - Full-year adjusted EBITDA totaled $24.3 million, compared to $11.7 million in the previous year [8] Guidance and Future Outlook - The company updated its 2026 revenue guidance to between $109 million and $114 million, with adjusted EBITDA expected to be between $21 million and $25 million [10] - The company is experiencing increased market volatility due to uncertainty surrounding Most Favored Nation (MFN) pricing, which may lead to some near-term headwinds [5] Share Repurchase Program - OptimizeRx's Board has authorized a $10 million share repurchase program, effective March 12, 2026, to be executed based on market conditions [11] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturers decreased to $2,838 in 2025 from $2,976 in 2024 [9] - Net revenue retention was 116% in 2025, down from 121% in 2024 [9] - Revenue per average full-time employee increased to $839 in 2025 from $701 in 2024 [9]

Revenue Performance - Q4 2025 revenue reached $32.2 million, consistent with Q4 2024 revenue of $32.3 million[5] - Full year 2025 revenue increased by 19% to a record $109.4 million, up from $92.1 million in 2024[5] - Net revenue for the year ended December 31, 2025, increased to $109,429,000, a 19% increase from $92,127,000 in 2024[25] Profitability - Q4 2025 gross profit rose 9% year-over-year to $24.1 million, compared to $22.0 million in Q4 2024[5] - Gross profit for the year ended December 31, 2025, was $73,595,000, compared to $59,378,000 in 2024, reflecting a 24% increase[25] - Q4 2025 GAAP net income was $5.0 million, a turnaround from a net loss of $(0.1) million in Q4 2024[5] - Net income for the year ended December 31, 2025, was $5,132,000, a significant recovery from a net loss of $20,110,000 in 2024[25] - Non-GAAP net income for the year ended December 31, 2025, was $19,867,000, compared to $6,162,000 in 2024, reflecting a significant improvement[30] Cash and Assets - Cash and cash equivalents increased to $23.4 million as of December 31, 2025, compared to $13.4 million a year earlier[5] - Total current assets increased to $64,715,000 as of December 31, 2025, up from $53,971,000 in 2024, representing an increase of 20%[23] - Cash and cash equivalents at the end of the period increased to $23,365,000 from $13,380,000, marking a 75% increase[27] Expenses and Liabilities - Operating expenses for the year ended December 31, 2025, decreased to $61,902,000 from $73,084,000 in 2024, a reduction of 15%[25] - Total liabilities decreased to $48,624,000 in 2025 from $54,170,000 in 2024, a reduction of approximately 10%[23] - The company repaid $8,000,000 in long-term debt during the year, compared to $4,000,000 in 2024, reflecting a commitment to reducing leverage[27] Guidance and Future Outlook - The company updated its 2026 revenue guidance to between $109 million and $114 million, with adjusted EBITDA guidance of $21 million to $25 million[7] Revenue Retention and Average Revenue - Net revenue retention for 2025 was 116%, down from 121% in 2024[6] - Average revenue per top 20 pharmaceutical manufacturers decreased to $2,838, down from $2,976 in 2024[6] Adjusted EBITDA - Adjusted EBITDA for Q4 2025 was $12.0 million, up from $8.8 million in Q4 2024[5] - Adjusted EBITDA for the year ended December 31, 2025, was $24,301,000, up from $11,730,000 in 2024, indicating a strong operational performance[31] Share Repurchase - The company authorized a $10 million share repurchase program effective March 12, 2026[8]